NOX-induced oxidative stress is a primary trigger of major neurodegenerative disorders

Yuri Zilberter1, Dennis R Tabuena2, Misha Zilberter2

  • 1Aix-Marseille Université, INSERM UMR1106, Institut de Neurosciences des Systèmes, Marseille, France.

Progress in Neurobiology
|October 14, 2023
PubMed

Insights

Oxidative stress from NADPH oxidase (NOX) activation may be a common trigger for neurodegenerative diseases (NDDs). Targeting this early oxidative stress could offer a preventative strategy for conditions like Alzheimer's and Parkinson's disease.

Area of Science:

  • Neuroscience
  • Pathology
  • Biochemistry

Background:

  • Neurodegenerative diseases (NDDs) present significant treatment challenges due to poorly understood initiating factors.
  • Shared risk factors and early pathologies in major sporadic NDDs suggest common initiation pathways.
  • Glucose hypometabolism and oxidative stress are early, shared pathologies implicated in NDDs.

Purpose of the Study:

  • To investigate NADPH oxidase (NOX) activation as a potential ubiquitous trigger for sporadic NDDs.
  • To explore commonalities in neuroinflammation and NOX involvement across Alzheimer's disease (AD), Parkinson's disease (PD), and epilepsy.
  • To identify potential therapeutic targets for NDDs by understanding shared initiating mechanisms.

Main Methods:

  • Review of recent research on oxidative stress and NDDs.
  • Analysis of commonalities in neuroinflammation and NOX pathways in AD, PD, and epilepsy.
  • Discussion of data supporting the proposed mechanisms in other NDDs.

Main Results:

  • NADPH oxidase (NOX) activation leading to early oxidative stress is proposed as a shared initiating mechanism in major sporadic NDDs.
  • Glucose hypometabolism and oxidative stress are identified as primary, early pathologies.
  • Neuroinflammation and NOX involvement are common features across studied NDDs.

Conclusions:

  • Targeting early oxidative stress caused by NOX activation may be a viable preventative strategy for multiple sporadic NDDs.
  • Understanding shared pathways like neuroinflammation and NOX activation is crucial for developing effective NDD therapeutics.
  • This research provides a framework for investigating a common trigger for diverse neurodegenerative conditions.

Related Concept Videos

Disorders of the Nervous Tissue01:28

Disorders of the Nervous Tissue

Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
1.4K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
579
Aging01:26

Aging

Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
60
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
503
Excitatory and Inhibitory Effects of Neurotransmitters01:29

Excitatory and Inhibitory Effects of Neurotransmitters

When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of...
10.0K